Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.81 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.81 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.81 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.81 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.81 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.81 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | NAMPT | P43490 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13949824 | 0.93 | HDAC1 (0.81) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13949855 | 0.92 | HDAC1 (0.92) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13949812 | 0.91 | HDAC1 (0.76) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13949813 | 0.91 | HDAC1 (0.79) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL8235160 | 0.90 | HDAC1 (0.82) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13949777 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13949830 | 0.90 | HDAC1 (0.92) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13949827 | 0.89 | HDAC1 (0.80) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL14394445 | 0.89 | HDAC1 (0.86) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL8234973 | 0.89 | HDAC1 (0.81) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387604-A1 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387604-A1 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | HDAC8, HDAC6, HDAC1 | HDAC1 3/4885HDAC3 7/4885HDAC4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.